Questions about this study?
The HopeStage team will email you.
Not recruitingEUCTR 2008-001581-91
A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with depression. Other eligibility criteria apply.
- Listed locations
- France · Germany and 4 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 840
- Sponsor
- Takeda Global Research & Development Centre (Europe) Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-001581-91
- Official title
Show the full official title
A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder
Recruitment & locations
Not recruitingFrance · Germany · Latvia
3 more locations
- Lithuania
- Netherlands
- United Kingdom
Registry details
Historical country statuses
- Germany — Completed
- France — Completed
- United Kingdom — Prematurely Ended
- Lithuania — Completed
- Latvia — Completed
- Netherlands — Completed
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Takeda Global Research & Development Centre (Europe) Ltd.
Who can participate?
This study is for people with depression. Other eligibility criteria apply.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...